01 January 2002
Drug-induced liver damage - a three-year study of patients from one gastroenterological department.
Marek Hartleb, Lukasz Biernat, Anna KochelMed Sci Monit 2002; 8(4): CR292-296 :: ID: 420865
Abstract
BACKGROUND: The aim of our study was to analyze drug-induced liver diseaseover a 3-year period in one gastroenterological department. MATERIAL/METHODS: International consensusstandard definitions and criteria for assessing causality of adverse drug reactions were applied to allpatients with abnormal hepatic test results. RESULTS: Drugs were implicated in hepatic injury in 14 patients(8 females) in whom causal relationship between drug and liver disease was definite or highly probable.The drugs responsible were amoxicillin with clavulanic acid (3 cases), fluvastatin and pravastatin (3cases), antituberculous drugs (2 cases), estrogens, roxithromycin, asacol, satolol, enalapril and thiamazol.A total of 78.6% (11 cases) were classified as hepatocellular or mixed hepatitis, while cholestatic injurywas found in 21.4% (3 cases). There were no lethal or severe (prothrombin < 50%) hepatic drug reactions.In 13 patients the course of liver disease after withdrawal of the offensive drug was either acute orprotracted, while in one patient there was chronic cholestasis (>3 years) resulting from injury to interlobularbile ducts by amoxicllin with clavulanic acid. CONCLUSIONS: A thorough history of drug intake shouldbe taken in all patients presenting with abnormal hepatic test results. Amoxicillin & clavulanic acid,cholesterol-lowering and antituberculin drugs were the most frequent hepatotoxic factors in our patients.In a majority of cases the liver injury was not severe, and resolved after prompt withdrawal of the responsibledrug.
Keywords: Anti-Bacterial Agents, Anti-Inflammatory Agents, Non-Steroidal, Anticholesteremic Agents, Antitubercular Agents, Comorbidity, enalapril, Estrogens, Fatty Liver, Hepatitis, Toxic, Liver Diseases, Mesalamine
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Clinical Research
Impact of Nurse-Led Versus Surgeon-Led Preoperative Counseling and Follow-Up on Postoperative Outcomes in P...Med Sci Monit In Press; DOI: 10.12659/MSM.945597
Clinical Research
Evaluation of Attitudes to Learning Doctor-Patient Communication Skills in 427 Postgraduate Doctors Using t...Med Sci Monit In Press; DOI: 10.12659/MSM.947276
Clinical Research
Exploring the Association Between Serum Neurogranin, Nardilysin, and Ischemic Stroke: A Case-Control Study ...Med Sci Monit In Press; DOI: 10.12659/MSM.947703
Clinical Research
Comparative Analysis of Laser Therapies for Striae Distensae: Fractional CO₂ vs Combined Q-Switch Nd:YAGMed Sci Monit In Press; DOI: 10.12659/MSM.947464
Most Viewed Current Articles
17 Jan 2024 : Review article 7,036,157
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,298
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,491
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 21,680
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912